Expression and clinical significance of phospholipase D1 in de novo acute myeloid leukemia

被引:2
作者
Lu, Ying [1 ,2 ]
Zhou, Jiasi [1 ,2 ]
Pei, Renzhi [1 ,2 ]
Li, Fenglin [3 ,4 ,5 ]
Jin, Jie [3 ,4 ,5 ]
Jiang, Lei [2 ]
机构
[1] Ningbo Univ, Dept Hematol, Affiliated Peoples Hosp, Ningbo, Peoples R China
[2] Ningbo Univ, Dept Pathol, Zhejiang Prov Key Lab Pathophysiol, Sch Med, Ningbo, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Peoples R China
[4] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
[5] Zhejiang Univ, Key Lab Hematol Malignancies Diag & Treatment, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Phospholipase D; acute myeloid leukemia; prognosis; CELL-PROLIFERATION; INHIBITION; AUTOPHAGY; ROLES;
D O I
10.1080/16078454.2020.1786971
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Phospholipase D (PLD) is known to participate in several aspects of cellular processes including cell mitosis, migration, phagocytosis, and membrane vesicle trafficking. The role of PLD has been investigated in multiple cancers except hematologic malignances. Methods: We enrolled 291 patients with de novo acute myeloid leukemia (AML) and detected PLD1 mRNA expression levels of their bone marrow samples by quantitative real-time PCR (qRT-PCR). Clinical relevance of PLD1 was assessed using Kaplan-Meier analysis, univariate analysis, and multivariate analysis. Results: Compared to healthy donors, AML patients had higher mRNA levels of PLD1, which was significantly associated with FAB classification. Importantly, patients with low levels of PLD1 had impaired overall survival and event-free survival. Moreover, univariate and multivariate analyses confirmed that PLD1 expression was an independent prognostic factor for AML. Conclusion: PLD1 represented a useful diagnostic marker and prognostic factor for AML.
引用
收藏
页码:270 / 275
页数:6
相关论文
共 26 条
[1]   Inhibition of mTOR-Dependent Autophagy Sensitizes Leukemic Cells to Cytarabine-Induced Apoptotic Death [J].
Bosnjak, Mihajlo ;
Ristic, Biljana ;
Arsikin, Katarina ;
Mircic, Aleksandar ;
Suzin-Zivkovic, Violeta ;
Perovic, Vladimir ;
Bogdanovic, Andrija ;
Paunovic, Verica ;
Markovic, Ivanka ;
Bumbasirevic, Vladimir ;
Trajkovic, Vladimir ;
Harhaji-Trajkovic, Ljubica .
PLOS ONE, 2014, 9 (04)
[2]   Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization [J].
Budczies, Jan ;
Klauschen, Frederick ;
Sinn, Bruno V. ;
Gyoerffy, Balazs ;
Schmitt, Wolfgang D. ;
Darb-Esfahani, Silvia ;
Denkert, Carsten .
PLOS ONE, 2012, 7 (12)
[3]   Key Roles for the Lipid Signaling Enzyme Phospholipase D1 in the Tumor Microenvironment During Tumor Angiogenesis and Metastasis [J].
Chen, Qin ;
Hongu, Tsunaki ;
Sato, Takanobu ;
Zhang, Yi ;
Ali, Wahida ;
Cavallo, Julie-Ann ;
van der Velden, Adrianus ;
Tian, Huasong ;
Di Paolo, Gilbert ;
Nieswandt, Bernhard ;
Kanaho, Yasunori ;
Frohman, Michael A. .
SCIENCE SIGNALING, 2012, 5 (249)
[4]   Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations [J].
Döhner, K ;
Schlenk, RF ;
Habdank, M ;
Scholl, C ;
Rücker, FG ;
Corbacioglu, A ;
Bullinger, L ;
Fröhling, S ;
Döhner, H .
BLOOD, 2005, 106 (12) :3740-3746
[5]  
Foster DA, 2003, MOL CANCER RES, V1, P789
[6]   Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].
Fröhling, S ;
Schlenk, RF ;
Breitruck, J ;
Benner, A ;
Kreitmeier, S ;
Tobis, K ;
Döhner, H ;
Döhner, K .
BLOOD, 2002, 100 (13) :4372-4380
[7]  
Fuss Ivan J, 2009, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0701s85
[8]  
Gomez-Cambronero Julian, 2014, Advances in Biological Regulation, V54, P197, DOI 10.1016/j.jbior.2013.08.006
[9]  
Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
[10]   Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial [J].
Jin, Jie ;
Wang, Jian-Xiang ;
Chen, Fei-Fei ;
Wu, De-Pei ;
Hu, Jiong ;
Zhou, Jian-Feng ;
Hu, Jian-Da ;
Wang, Jian-Min ;
Li, Jian-Yong ;
Huang, Xiao-Jun ;
Ma, Jun ;
Ji, Chun-Yan ;
Xu, Xiao-Ping ;
Yu, Kang ;
Ren, Han-Yun ;
Zhou, Yu-Hong ;
Tong, Yin ;
Lou, Yin-Jun ;
Ni, Wan-Mao ;
Tong, Hong-Yan ;
Wang, Hua-Feng ;
Mi, Ying-Chang ;
Du, Xin ;
Chen, Bao-An ;
Shen, Yi ;
Chen, Zhu ;
Chen, Sai-Juan .
LANCET ONCOLOGY, 2013, 14 (07) :599-608